Background: Outcomes of radiotherapy (RT) compared with chemotherapy (CT) remain poorly defined for clinical stage (CS) IIA and IIB seminoma. We aimed to evaluate the current role of the two treatment modalities in this setting of testicular seminoma.
introduction Testicular germ-cell tumors are highly curable neoplasms even in advanced stages. Pure seminomas exhibit an excellent sensitivity to both chemotherapy (CT) and radiotherapy (RT), with exceptionally high cure rates when administered alone or whenever consolidation RT following primary CT is needed [1] . For this reason, in recent years, attempts to improve the outcome across the clinical settings have focused mostly on sparing patients unnecessary or excessive treatments to alleviate side-effects, mostly long-term toxicities. Advanced seminoma presents with retroperitoneal nodal disease in the vast majority of cases, and if, on one hand, there is little or no debate about the indication of CT in cases with bulky disease [i.e. lymph nodes >5 cm in greatest dimension, clinical stage (CS) IIC] much controversy exists regarding the optimal choice between CT and RT for CSs IIA and IIB (i.e. lymph nodes <2 and 2-5 cm in greatest dimension, respectively). Presently, a few retrospective series and prospective noncomparative studies are available, and usually with small number of patients each, and no definitive recommendations exist regarding the superiority of one option over the other. While overall survival (OS) is almost 100% irrespective of treatment, relapse-free survival (RFS) approximates 90% and differential outcomes between CT and RT have been poorly analyzed in depth . Furthermore, toxicities following each treatment modality are still a critical issue, particularly regarding the longterm side-effects and the incidence of second neoplasms. Cisplatin-based CT is established as the standard first-line therapy for metastatic germ-cell tumors (GCTs). Three cycles of cisplatin, etoposide, and bleomycin (PEB) or four cycles of cisplatin and etoposide (EP) CT are both acceptable options [30] . The standard radiation field now in use for CSII seminoma comprises paraortic region and ipsilateral iliac nodes termed the dog-leg field, but larger volumes, heterogeneous doses (the current standard being 30-36 Gy), and prophylactic irradiation of supradiaphragmatic regions have been applied in the past and should be accounted for when evaluating results.
Regarding CSIIB in particular, although robust data supporting the equivalence of RT and CT are still lacking, they are both employed in clinical practice. Besides the efficacy end points, the impact of each treatment modality on the incidence of second cancers and late complications in the setting of metastatic seminoma is unclear. Presumably data generated from CS I seminoma cannot be extrapolated to patients with advanced disease, given the differences in dose and field. In light of these critical issues and the paucity of data on RT and CT for this specific patient subset, we carried out a systematic review and meta-analysis (MA) of currently available evidences to better analyze the contemporary role of each treatment modality, to provide practical recommendations, and to pinpoint the unmet needs that prospective clinical trials should address.
patients and methods

search strategy and data abstraction
We carried out a systematic review and MA in accordance to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines [31] .
Eligible studies were searched in PubMed, Embase, and meeting abstracts presented at congresses of the American Society of Clinical Oncology (ASCO), Genitourinary Cancers Symposiums, European Society for Medical Oncology (ESMO), American Urological Association (AUA), and American Society for Radiation Oncology (ASTRO) until April 2014.
The following inclusion criteria have been adopted: period of publication between 1990 and 2014, retrospective and prospective trials/studies reporting data on any CT regimen or RT modality for CSIIA and/or CSIIB seminoma patients. Principal exclusion criteria were overlapping publications, lack of outcome data relative to CSII, studies entirely reporting on patients treated before 1990, and studies reporting on chemoradiation strategies.
To be comprehensive, the search string 'seminoma' AND 'chemotherapy' AND 'radiotherapy' was applied and additional queries with relevant variants have been added up. Search results were independently reviewed by two authors (PG and AN). Full articles were retrieved for further qualitative review.
The primary end point was the relapse rate (RR). Secondary end points were the incidence of acute, long-term toxicities and second cancers, and mortality rate. RFS was commonly defined as the time from the date of starting treatment to the date of documented relapse or recurrence, while OS was defined as the time from treatment start to death for any reason, with censoring alive patients at the date of last contact.
statistical analysis
Effect measures of the outcomes of RFS and OS were the incidence of event with 95% confidence interval (CI), which was obtained by extracting the study-specific proportion of patients with the outcome events, using the continuity correction when there are empty cells. Pooled incidences were calculated using a fixed-effects or random-effects model depending on the heterogeneity of included studies. Statistical heterogeneity was tested by means of Cochran Q test, with statistical significance set at the two-tailed 0.10 level, whereas extent of statistical consistency was measured with I 2 [32] . When substantial statistical inconsistency was not observed (I 2 < 25%), the summary estimate was calculated based on the fixed-effects model using the inverse variance method. When heterogeneity was observed, the summary estimate was calculated based on the random-effects model using the DerSimonian and Laird method that considers both within-and between-study variations. The individual 95% CIs was calculated by means of normal approximation. The zero-event trials are included applying the standard continuity correction of 0.5.
sensitivity, influence analyses, and publication bias
We first analyzed the overall population of patients receiving RT or CT. Then we carried out subgroup analyses by independently analyzing the effect of RT or CT in the following subgroup of patients: CSIIA and CSIIB, dog-leg RT in both the CSs, RT dose (by dichotomizing between ≥30 and <30 Gy), and CT regimen PEB or EP only. To evaluate the effect of the treatment (RT versus CT) and of median follow-up, we used a generalized linear model, with binomial response and the link logit function, that allows to modeling the risk of event incorporating the correlation within the two-arm studies and the different covariance contributions for the RT and CT groups [33] . Results were presented as odds ratios with their 95% CIs.
Publication bias was evaluated by visually inspecting funnel plots of the primary outcome and by analytical appraisal based on the Egger's and Peters' linear regression test (a two-sided P value of ≤0.10 was regarded as significant) fitting a generalized linear model with binomial response and link logit [34, 35] .
We also carried out influence analyses, whereby we removed each study one at a time to determine the impact on the overall pooled result. In addition, we carried out sensitivity analyses on studies depending on the proportion of patients included and by selecting only those studies with more than 50 patients.
Statistical significance was set at the two-tailed 0.05 and P values are reported throughout. Analyses were carried out using STATA 11.0 Software (StataCorp LP, College Station, TX).
results
search results
We identified a total of 717 studies using the search criteria, published between 1990 and 2013. Figure 1 outlines the selection process and reasons for study exclusion. A total of 13 studies were selected for the MA, including 4 prospective and 9 retrospective studies accounting for a total of 890 assessable patients (607 for RT and 283 for CT, Table 1 ). We found four non-randomized studies comparing RT versus CT, while the remaining investigated RT or CT series alone.
Among the RT studies, six reported data on paraortic/ paracaval + ipsilateral iliac fields only, while the other studies included mediastinal ± supraclavicular fields and one further study a scrotal field. RT doses were highly heterogeneous as documented by Table 1 . Among the CT studies, three reported the results of either PEB or EP CT, while the others reported on the following regimens: HOP (ifosfamide, vincristine, cisplatin), PVB (cisplatin, vinblastine, bleomycin), modified VAB (vinblastine, cyclophosphamide, dactinomycin, bleomicin), and single-agent carboplatin (CBDCA). The overall median followup for RT studies was 90 months (range 36-228 months), and for CT studies was 72.2 months (range 28-112.8 months).
meta-analyses and sensitivity analyses for relapse outcome
For the end point of RR, 13 studies were analyzed (Table 2 and Figure 2A and B). In the primary analysis, the pooled RR was similar between the RT [0.11 (95% CI 0.08-0.14), P for heterogeneity = 0.096, I 2 = 38%, with 11 studies included] and CT groups [0.08 (95% CI 0.01-0.15), P for heterogeneity <0.001, I 2 = 82.5%, with 6 studies included]. Furthermore, the meta-regression model that evaluated the effect modifier of RT respect to CT on relapse risk did not report significant differences overall between the two groups [odds ratio = 1.26 (95% CI 0.35-4.56), P = 0.613, supplementary Table S1 , available at Annals of Oncology online]. Of note however, the sensitivity analysis selecting current RT and CT standards (i.e. paraortic + iliac RT and PEB/EP CT) showed an apparent difference in the RR of CSIIB following RT (0.12, 95% CI 0.06-0.17) compared with CT (0.05, 95% CI 0-0.11), as shown in Table 2 . The odds ratio of RT for CSIIB in the meta-regression model was 2.17 (95% CI 0.31-15.09), although not statistically significant (P = 0.227). On the contrary, results for CSIIA in the same sensitivity analysis were overlapping: RR of 0.05 (95% CI 0.02-0.07) for RT and 0.07 (95% CI 0-0.19) for CT. The generalized linear model fitted to assess the influence of average follow-up against the log incidence of relapses showed no significant effects [slope coefficient = 0.005 (95% CI −0.008 to 0.018), P = 0.224].
Publication bias analysis revealed a presence of residual heterogeneity (supplementary Figure S1 , available at Annals of Oncology online). Besides, the discordance between the Egger test (P = 0.013 and P = 0.094, for RT and CT, respectively) and Peters test (P = 0.175 and P = 0.387, for RT and CT, respectively) suggested a possible effect of the smallest studies on the pooled estimate. However, the overall results were confirmed when including only studies with more than 50 patients: the pooled RR for RT [0.10 (95% CI 0.06-0.14), P for heterogeneity = 0.059, I 2 = 56.1%, with 5 studies included] was equivalent to CT [0.08 (95% CI 0.0-0.19), P for heterogeneity <0.001, I 2 = 92%, with 3 studies included]. The odds ratio of the meta-regression model was 1.05 (95% CI 0.22-4.99, P = 0.937).
Influence analyses for RT and CT are shown in Figure 3A and B, respectively. The overall RR ranged from 0.07 to 0.15 and from 0 to 0.18 for RT and CT, respectively. Among the RT studies, none seemed to have an important impact on the overall relapse incidence, while the Krege study among the CT studies was the most influential [23] .
meta-analyses and sensitivity analyses for mortality outcome
For the end point of mortality rate, eight studies were available (+ Hallemeier's study for CSIIB only [27] , supplementary Table S2 , available at Annals of Oncology online, and Figure 2C and D). The pooled mortality rate was similar using RT [0.02 (95% CI <0.01-0.04), P for heterogeneity = 0.017, I 2 = 63.7%, with six studies included] or CT [0.01 (95% CI <0.01-0.02), P for heterogeneity = 0.319, I 2 = 14.6%, with four studies included]. Sensitivity analyses are also shown in supplementary Table S2 , available at Annals of Oncology online. Including only studies reporting on either paraortic + iliac RT or PEB/EP CT the pooled mortality rate was 0.01 (95% CI <0.01-0.02, P for heterogeneity = 0.142, I 2 = 39.5%, with six studies included) for RT and 0.02 (95% CI 0-0.05, P for heterogeneity = 0.175, I 2 = 42.7%, with three studies included) for CT, respectively. Results obtained by singly analyzing the patient population of CSIIA and CSIIB were highly affected by small numbers, as provided.
The overall results when including only studies with more than 50 patients were as follows: the pooled mortality rate for RT [0.01 (95% CI <0.01-0.02), P for heterogeneity = 0.006, I 2 = 76%, with four studies included] was still identical to CT [0.01 (95% CI 0-0.02), P for heterogeneity = 0.22, I 2 = 35%, with three studies included].
incidence of acute toxicities, late sequelae, and second cancers Table 3 provides the results of studies reporting on the sideeffects of treatments. For this purpose, we included two additional studies that were not evaluable for the primary efficacy end point [36, 37] . While acute side-effects were reported The overall incidence of nontesticular second malignancies was 0.04 (95% CI 0.01-0.02) in the RT group and 0.02 (95% CI 0.003-0.04) in the CT group. In detail, looking at the RT studies, the actuarial 15-year risk of second nontestis neoplasm was 6% in Bauman's series [17] and 8% in Garcia-Serra's study [36] , while the 30-year risk was 16% in Hallemeier's study [37] . Five cases (6%) of second cancers have been reported by Patterson et al. after a median of 134.4 months follow-up [20] . All second cancers occurred in the irradiated field in Patterson's and Domont's series [20, 28] , 9/12 in Hallemeier's [27] , and either in-or outside the field in the rest.
discussion
RT and CT appeared to be similarly effective overall in CSIIA and IIB seminoma, but CT demonstrated a trend toward lower incidence of side-effects and RR in CSIIB disease. To the best of our knowledge, this is the first systematic review and MA focused on CS IIA and IIB seminoma. Despite the exceptional overall cure rate, this field is still fraught with difficulties for two main reasons. First, randomized prospective studies that may provide guidance are still lacking, secondly a high burden of treatment (i.e. that of metastatic disease) is required and consequently the choice of different treatment options is even more impactful at long-term than that observed for stage I after one cycle of carboplatin CT or RT at lower doses.
To be comprehensive, we allowed inclusion of non-cisplatinbased regimens as well as of regimens other than PEB/EP, despite these being no longer the standard clinical practice. In the Results of this phase II study, reporting a relapse rate of 19.6% (10 of 51 patients) in CSIIA with the use of carboplatin alone, accounted for the overall apparent superiority of RT over CT in this stage (0.05 versus 0.14 relapse rate for RT and CT, respectively, and odds ratio of 0.47 for RT over CT in supplementary Table S1 , available at Annals of Oncology online), while outcomes were overlapping in the sensitivity analysis on standard treatments alone. Moreover, the same study is likely to be reason of the observed heterogeneity in relapse outcome that is evident in the funnel plots of supplementary Figure S1 , available at Annals of Oncology online. Such a comprehensive approach is important in our view to underscore once again the disconnect between the results with the use of cisplatin versus carboplatin-based regimens in advanced disease. We acknowledge several limitations of our MA, most importantly that this was a study-level MA and that almost all the available results were of retrospective or noncomparative quality. Hence, the analysis was built on the relative risks rather than hazard ratios, with the limit that most of common meta-analytic techniques have not been applied in this context yet.
For the above reasons, the comparison between the RT and CT groups, which was evident in the overlapping CIs of the forest plot, was further quantified by using a generalized linear model with the binomial distribution and the logit as link function, which well accommodate count or rate data. Bauman (1998) Chung (2004) Chung (2004) Classen (2003) Domont (2013) Domont (2013) Hallemeier (2013) Kollmannsberger (2011) Patterson (2001) Sridharan (2013) Sridharan (2013) Tandstad (2011) Tandstad (2011) Weissbach (1999) Zagars (2001) 0.07 0.08 0.11 0.14 0.15
Meta-analysis estimates, given named study is omitted Lower CI Type of side-effect Acute toxicity (n) Late toxicity (n) Second cancers (n)
Garcia-delMuro et al. [24] 2008 72 CT EPx4/BEPx3 71.5 All grades: Granulocytopenia (27) . Thrombocytopenia (9) . Anemia (4). FN (8) . Vomiting (33) . Mucositis (6) . Diarrhea (2) . Pulmonary toxicity (1). Peripheral neuropathy (14) . Skin rash (3). Ototoxicity (2) . Alopecia (72). Grade 3-4: Granulocytopenia (9). Thrombocytopenia (2). Anemia (1) . FN (8) . Vomiting (6) . Mucositis (1). Diarrhea (1) . Pulmonary toxicity (1). We also incorporated in the model the correlation within the two-arm studies and the different covariance contributions for the RT and CT groups. We could not exclude the possible influence of patient selection factors and small-study effects on the results of our MA even if overall results were confirmed when we included only the largest trials (i.e. more than 50 patients). Furthermore, traditional limitations of meta-analyses, mainly attributable to variations of RT doses, fields, ad techniques, in populations or major subgroups within trials, as well as in study conduct apply to the present analysis [38, 39] . This is the reason why sensitivity analyses attempted to dissect the contribution of studies with either paraortic + iliac RT only and doses ≥30 or <30 Gy. Additional limitations are that many patients, especially in the RT group, were staged before the routine adoption of computer tomography scanning and that we could not dissect if a selection bias existed favoring the inclusion of less fit patients in the RT group.
In light of these limitations, the uncertainty of physicians to utilize RT or CT, particularly in CSIIB seminoma, is understandable. Despite in fact of the substantial overlap in efficacy outcomes for CSIIA, a double relapse rate (0.12 versus 0.05) was found for RT compared with CT in CSIIB, documented by an odds ratio of 2.17 for RT overall. Although not statistically significant (P = 0.227), this difference could be clinically meaningful and warrants confirmation in clinical trials.
Looking at the available recommendations, in Europe, the 2014 European Association of Urology (EAU) guidelines consider CT as an alternative to RT for CSIIB [40] , while the 2013 clinical practice guidelines of the European Society for Medical Oncology (ESMO) did provide CT as the optimal choice [41] . Internationally, the National Comprehensive Cancer Network (NCCN) guidelines, in version 1.2014, claimed RT as the primary choice for CSIIA and IIB, and primary CT as the preferred option over RT in selected high-risk CSIIB cases [42] . Additional information that is required in setting the relative role of the two treatments refers to the incidence of side-effects and second neoplasms. Despite the intrinsic caveats of retrospective data, since acute and late toxicities are not usually recorded formally or consistently off-protocol, we were able to shed light on interesting findings. First, the occurrence of cases of contralateral testicular tumors was reported only after RT, and this actually reflects the results of available studies including the post hoc analysis of the MRC/EORTC randomized phase III trial of carboplatin compared with RT for stage I seminoma [43] . Indeed, caution is needed because the median follow-up was longer for RT than CT but still too short (7.5 years overall) to recognize a potential impact of CT in delaying rather than eradicate this phenomenon and because some of these studies actually included stage I and IIC patients as indicated in Table 3 . Secondly, the overall incidence of second neoplasms trended toward an association with RT (double incidence compared with CT) as already reported by other authors [44] . The majority of nontesticular solid cancers occurred in irradiated fields and they were represented by adenocarcinomas of the gastrointestinal tract. Finally, the incidence of late sequelae trended again toward RT pretreatment and they were represented by gastrointestinal side-effects, according to existing data [45] . Again, data warrant additional follow-up as the occurrence, for example, of cardiovascular diseases (not reported in the studies analyzed) has been recognized after an average of 15 years of follow-up after CT for testicular cancer [45, 46] . Likewise, the impact of modern RT techniques might be smaller than expected as authors recently suggested [47] . Taken together, critical evidences collected thus far are suggesting an erosion of equipoise in favor of CT for CS IIB seminoma, although additional evidences should be collected in order to define the latter as the standard option for these patients outside clinical trials. Of course trials comparing modern RT devices with CT should be guided by the thorough evaluation of acute and long-term toxicities in order to provide substantial improvements in the field.
In addition to the evaluated studies in fact, there are presently two ongoing studies investigating the efficacy and safety of proton RT in CSI and II seminoma (ClinicalTrials.gov number NCT01557790) and the combination therapy with single-agent carboplatin plus involved field RT (ClinicalTrials.gov number NCT01593241). The challenge of the chemoradiation study will be to improve the present negative results with carboplatin alone in CSII seminoma. There are no ongoing studies to our knowledge with novel CT regimens that allow the inclusion of CSII seminoma or other good prognosis GCT.
conclusion
To summarize, we provided a comprehensive analysis of the results of RT and CT for CSIIA and CSIIB testicular seminoma, including efficacy and safety issues. Despite the statistical equivalence between the two modalities across the CSs and treatment patterns, a difference in the trend of relapses was observed favoring the use of CT in CSIIB. This information, together with the observed (confirmed) incidence of late toxicities and second cancers after RT, actually provides a valuable proof of principle for the use PEB/EP CT as the preferred choice for all stage II cases. Present findings warrant validation in prospective clinical trials and represent a call for publication of further case series on this topic.
